Ocugen (OCGN) closed at $0.93 on November 6, 2026, up 13.2% from the previous close, on volume of 7,287,655 shares (30-day average 6,487,893).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | ITM Risk Reversal or Strangle | 21-Jan-281 P : 1.5 C | 1,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Ocugen’s Retinal Gene-Therapy Catalysts Support Unchanged $11 Price Target Despite Cash Overhang
TipRanks (Thu, 5-Nov 5:36 PM ET)
Analysts Have Conflicting Sentiments on These Healthcare Companies: RxSight (RXST) and Ocugen (OCGN)
TipRanks (Wed, 4-Nov 4:30 PM ET)
Ocugen GAAP EPS of -$0.01 beats by $0.05, revenue of $1.95M beats by $1.17M
Seeking Alpha News (Wed, 4-Nov 7:08 AM ET)
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Ocugen Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 10:25 AM ET)
Ocugen to Participate in Upcoming November Investor and Industry Conferences
Globe Newswire (Thu, 29-Oct 7:02 AM ET)
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Globe Newswire (Thu, 22-Oct 7:00 AM ET)
Globe Newswire (Wed, 14-Oct 6:30 AM ET)
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Thu, 8-Oct 2:51 PM ET)
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Globe Newswire (Tue, 6-Oct 7:02 AM ET)
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ocugen trades on the NASDAQ stock market under the symbol OCGN.
As of November 6, 2026, OCGN stock price climbed to $0.93 with 7,287,655 million shares trading.
OCGN has a beta of 0.27, meaning it tends to be less sensitive to market movements. OCGN has a correlation of 0.00 to the broad based SPY ETF.
OCGN has a market cap of $313.68 million. This is considered a Small Cap stock.
Last quarter Ocugen reported $2 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.01.
In the last 3 years, OCGN traded as high as $2.73 and as low as $.35.
The top ETF exchange traded funds that OCGN belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
OCGN has underperformed the market in the last year with a return of -33.0%, while the SPY ETF gained +10.8%. In the last 3 month period, OCGN fell short of the market, returning -25.4%, while SPY returned -4.1%. However, in the most recent 2 weeks OCGN has outperformed the stock market by returning +25.1%, while SPY returned -3.2%.
OCGN support price is $.77 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCGN shares will trade within this expected range on the day.
